Alpha cognition to present zunveyl® (benzgalantamine) study data at alzheimer's association international conference

Vancouver, british columbia & dallas--(business wire)--alpha cognition inc. (nasdaq: acog) (“alpha cognition” or the “company”), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical data on zunveyl at the alzheimer's association international conference (aaic), taking place july 27–31, 2025, in toronto, canada. the company will share the following poster presentations: bioequivalence of zunveyl,.
ACOG Ratings Summary
ACOG Quant Ranking